Aqilion focuses on diseases caused by chronic inflammation and dysfunctional immunological reactions

We explore novel scientific findings describing the biology behind the diseases and focus on developing new innovative treatments. Our mission is clear, we identify opportunities based on solid research resting on a firm biological foundation offering both clinical relevance and patient benefit.

Sarah Fredriksson, CEO, presents Aqilion:

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion’s experienced team and board have successfully shepherded drugs all the way from discovery to market.

Main focus is to expand Aqilion’s project portfolio within chronic inflammation and immunology.

Our aspiration is for the results of our work to improve patient quality of life, while also managing a project portfolio that appeals to both Aqilion owners and customers.


Read more about our Protection of your personal data.